Mariette Labots
Mariette Labots
Medical oncologist, VU University Medical Center, Amsterdam
Verified email at
Cited by
Cited by
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance
KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ...
Clinical Cancer Research 17 (23), 7337-7346, 2011
Pan-cancer whole-genome analyses of metastatic solid tumours
P Priestley, J Baber, MP Lolkema, N Steeghs, E de Bruijn, C Shale, ...
Nature 575 (7781), 210-216, 2019
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
L Angus, M Smid, SM Wilting, J van Riet, A Van Hoeck, L Nguyen, ...
Nature genetics 51 (10), 1450-1458, 2019
Genomic landscape of metastatic colorectal cancer
JC Haan, M Labots, C Rausch, M Koopman, J Tol, LJM Mekenkamp, ...
Nature communications 5 (1), 1-12, 2014
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
DL van der Velden, LR Hoes, H Van Der Wijngaart, ...
Nature 574 (7776), 127-131, 2019
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study
D de Wit, NP van Erp, J den Hartigh, R Wolterbeek, ...
Therapeutic drug monitoring 37 (3), 331-338, 2015
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics
JC van der Mijn, M Labots, SR Piersma, TV Pham, JC Knol, ...
Journal of proteomics 127, 259-263, 2015
Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods
SR Piersma, M Labots, HMW Verheul, CR Jiménez
Analytical and bioanalytical chemistry 397 (8), 3163-3171, 2010
Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines
SR Piersma, JC Knol, I de Reus, M Labots, BK Sampadi, TV Pham, ...
Journal of proteomics 127, 247-258, 2015
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells
E Giovannetti, M Labots, H Dekker, E Galvani, JSW Lind, R Sciarrillo, ...
Current pharmaceutical design 19 (5), 927-939, 2013
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
R Beekhof, C van Alphen, AA Henneman, JC Knol, TV Pham, F Rolfs, ...
Molecular systems biology 15 (4), e8250, 2019
Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
M Labots, KJ Gotink, H Dekker, K Azijli, JC Van Der Mijn, CM Huijts, ...
Experimental & molecular medicine 48 (12), e279-e279, 2016
Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection
M Labots, JC van der Mijn, R Beekhof, SR Piersma, RR de Goeij-de Haas, ...
Journal of proteomics 162, 99-107, 2017
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies
M Labots, LM Schütte, JC van der Mijn, TV Pham, CR Jiménez, ...
The oncologist 19 (10), 1028, 2014
Sex-and site-specific differences in colorectal cancer risk among people with type 2 diabetes
JA Overbeek, JG Kuiper, AAWA van der Heijden, M Labots, U Haug, ...
International journal of colorectal disease 34 (2), 269-276, 2019
High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection
M Labots, TE Buffart, JC Haan, NCT van Grieken, M Tijssen, ...
Cellular oncology 37 (1), 41-52, 2014
Phase I dose-escalation study of once weekly or once every two weeks administration of high-dose sunitinib in patients with refractory solid tumors
M Rovithi, SL Gerritse, RJ Honeywell, AJ Ten Tije, R Ruijter, GJ Peters, ...
Journal of Clinical Oncology 37 (5), 411, 2019
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
M Labots, TV Pham, RJ Honeywell, JC Knol, R Beekhof, ...
Cancers 12 (2), 330, 2020
The genomic landscape of 501 metastatic breast cancer patients
L Angus, SM Wilting, J van Riet, M Smid, TG Steenbruggen, ...
CANCER RESEARCH 79 (4), 2019
Tumor, skin, and plasma concentrations of protein kinase inhibitors (PKIs) in patients with advanced cancer.
M Labots, M Neerincx, JC Van der Mijn, H Dekker, R Honeywell, ...
Journal of Clinical Oncology 31 (15_suppl), 11087-11087, 2013
The system can't perform the operation now. Try again later.
Articles 1–20